Clinical trials: Pituitary Diseases
GHD
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.
- Trial name
- ELEVATE (NCT06007417)
- Testing
- GenSci004, Genotropin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
- Trial name
- TAUBER (NCT00156143)
- Testing
- Blood sample, Radiography
- Volunteers
- 90 people
- Sponsor
- Pfizer
Growth Hormone Deficiency
Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
The purpose of the study is to evaluate the safety and effectiveness of ALTU-238 in the treatment of children with growth hormone deficiency who have not yet reached puberty who lack the normal ability to make growth hormone…
- Trial name
- NCT00837863
- Testing
- Somatropin
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Altus Pharmaceuticals
Acromegaly
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
- Trial name
- NCT00216398
- Testing
- Lanreotide (Autogel formulation)
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Ipsen
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Female Infertility
Multiple Dose FSH-GEX(TM) in Healthy Volunteers
The aim of the current study is the pharmacokinetic and pharmacodynamic characterization of a multiple dose administration of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator…
- Trial name
- NCT01477073
- Testing
- FSH-GEX™, recombinant FSH, urinary FSH
- Where
- Netherlands
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Glycotope GmbH
Antidiuretic Hormone, Inappropriate Secretion
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
- Trial name
- NCT04790175
- Testing
- Tolvaptan (SAMSCA)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Hyponatremias, Water Intoxication
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment.
- Conditions
- Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
- Trial name
- NCT00072683
- Testing
- tolvaptan
- Where
- 23 sites in United States
- Volunteers
- 205 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acromegaly
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or…
- Trial name
- LEAD (NCT00701363)
- Testing
- Lanreotide Autogel 120 mg
- Where
- 44 sites in Brazil, Denmark and 12 more
- Volunteers
- 124 people
- Sponsor
- Ipsen
Growth Hormone Deficiency (GHD)
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive…
- Trial name
- NCT06948214
- Testing
- LUM-201
- Where
- 55 sites in United States, Argentina and 6 more
- Volunteers
- 150 people
- Sponsor
- Lumos Pharma
Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
- Trial name
- NCT00151437
- Testing
- Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire
- Where
- 5 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Pituitary Disorders, Adult Growth Hormone Deficiency
Treatment of Adults With Growth Hormone Deficiency
The objective of this rollover study is to evaluate the long term (1 year) safety of a new weekly administered growth hormone preparation in adults with growth hormone deficiency who were treated with the same experimental…
- Trial name
- NCT00596037
- Testing
- Growth hormone - LB03002
- Volunteers
- 136 people
- Sponsor
- LG Life Sciences
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
This trial is conducted in Europe. Growth Hormone in young adults with growth hormone deficiency in childhood. This trial compares a treated group of patients with an untreated group of patients.
- Trial name
- NCT00184678
- Testing
- somatropin
- Where
- 30 sites in Australia, Austria and 10 more
- Volunteers
- 161 people
- Sponsor
- Novo Nordisk A/S
Acromegaly
Open Label Study of Octreotide Implant in Patients With Acromegaly
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of treatment.
- Trial name
- NCT00913055
- Testing
- octreotide acetate
- Volunteers
- 34 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Growth Hormone Deficiency
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early…
- Trial name
- NCT00191165
- Testing
- Somatropin
- Where
- 10 sites in Italy
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Infertility
An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)
The objectives of this study were to study the pharmacokinetics, pharmacodynamics and safety of Org 36286 after a single subcutaneous administration in healthy females.
- Trial name
- NCT00647933
- Testing
- Org 36286, Lyndiol®
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Organon and Co